Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

Authors not listed

EyePoint Pharmaceuticals, Inc. · 2024

Abstract

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Anonymous. (2024). A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD. <em>EyePoint Pharmaceuticals, Inc.</em>. https://clinicaltrials.gov/study/NCT06668064
Vancouver
Anonymous. A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD. EyePoint Pharmaceuticals, Inc.. 2024.
BibTeX
@misc{anon2024AyearP, title = {A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD}, author = {Anonymous}, journal = {EyePoint Pharmaceuticals, Inc.}, year = {2024}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings